Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Samir H. Barghout, BSPharm, MSc, Parasvi Patel, BSc (Hons), Xiaoming Wang, G. Wei Xu, Simon Kavanagh, Marcela Gronda, MSc, Rose Hurren, BSc, Danny V. Jeyaraju, PhD, Neil MacLean, Marc Hyer, PhD, Allison Berger, PhD, Tary Traore, Michael Sintchak, Michael Milhollen, Mark D. Minden, MD PhD, Razq Hakem, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 814.

https://doi.org/10.1182/blood.V130.Suppl_1.814.814

Published: 2017

Journal Articles

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Jörg Uwe Schmohl, MD, Martin Felices, PhD, Jeffrey S. Miller, MD, Dan Vallera, PhD

Blood (2016) 128 (22): 3518.

https://doi.org/10.1182/blood.V128.22.3518.3518

Published: 2016

Journal Articles

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Annalisa Andreoli, MD, Emmanuelle Verger, PhD, Marie Robin, MD, PhD, Emmanuel Raffoux, Jean-Marc Zini, MD, PhD, Philippe Rousselot, MD, PhD, Gérard Socié, MD, PhD, Delphine Rea, MD, PhD, Nathalie Parquet, MD, Stephane Giraudier, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 1591.

https://doi.org/10.1182/blood.V122.21.1591.1591

Published: 2013

Journal Articles

A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.

Michael C. Heinrich, MD, Jason R. Morich, Emmanuel J. Beillard, Ph.D., Courtney Fuller, Chad D. Galderisi, D.O., Brian J. Druker, M.D.

Blood (2006) 108 (11): 2334.

https://doi.org/10.1182/blood.V108.11.2334.2334

Published: 2006

Journal Articles

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

M. Gorre, H. Kantarjian, I. Jilani, J. Cortes, A. Salvado, P. Rae, L. Alland, M. Dugan, O. Ottmann, K. Bhalla, F. Giles, M. Albitar

Blood (2005) 106 (11): 2001.

https://doi.org/10.1182/blood.V106.11.2001.2001

Published: 2005

NARROW

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

Email alerts

ASH Publications

American Society of Hematology

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only